Cempra, a biopharmaceutical company focused on the treatment of bacterial infectious diseases, announced terms for its IPO on Friday, with pricing set for the week of January 30th. The Chapel Hill, NC-based company, founded in 2005, plans to raise $72 million by offering 6 million shares at a price range of $11.00 to $13.00. At the midpoint of the proposed range, Cempra will command a market value of $195 million. Although it has yet to generate revenues, its top two product candidates have both passed Phase 2 clinical trials. Venture capital firms Intersouth Partners, Aisling Capital, Quaker BioVentures and Blackboard Ventures are listed as principal stockholders. Cempra plans to list on the NASDAQ under the symbol CEMP. Stifel Nicolaus Weisel, Leerink Swann, Cowen and Company and Needham & Company are the lead underwriters on the deal.
